Fig. 2From: Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATEThe contribution to the cumulative absorbed dose to the tumour from each cycle of therapy for each of the six patients (P1-P6), with the median values shown in the last bar. The numbers in the bars represent the absolute values of the tumour absorbed dose in GyBack to article page